Worldwide Clinical Trials Uses its CNS Excellence to Support Huntington’s Disease Research
Huntington’s disease was first described in the 1800s and is now known to be caused by a defective gene on chromosome 4. There is still no cure for the disease and no known strategy to slow down its progress. Thus, current treatment therapies focus on management of symptoms, some of which are physical, some behavioral, and some cognitive in nature.
With over 30 years of experience in rare disease studies, Worldwide Clinical Trials is a recognized leader in rare disease clinical research. Our presence in 60+ countries enables us to administer investigative sites and patient enrollment with a feet-on-the-ground understanding of regional regulations and cultural/language considerations. We are adept at designing and executing challenging trials, flexing to find strategies to optimize your investment for successful results in your Huntington’s disease clinical trial.